{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273250","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.187506+00:00","generated_at":"2026-05-16T22:41:33.680456+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee Q3 net loss $65M; APG333 half-life ~55 days supports quarterly dosing; cash $913M, runway into 2H 2028","bullets":["Q3 2025 net loss $65.0M vs $49.0M YoY; cash and securities $588.9M pre-offering, $913M pro forma post-$345M equity offering.","APG333 Phase 1 data: half-life ~55 days, biomarker suppression for 6 months, well tolerated up to 1000 mg; supports quarterly or better dosing for APG273 co-formulation.","APG777 readouts accelerated: Phase 1b asthma data Q1 2026; APEX Part A 52-week data Q1 2026; APEX Part B 16-week data Q2 2026; Phase 3 start 2H 2026.","APG279 (APG777+APG990) head-to-head vs DUPIXENT in AD interim readout expected 2H 2026.","Cash runway extended into 2H 2028 through Phase 3 topline data for APG777."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273250","json":"https://secwatch.observer/filing/0001193125-25-273250.json","markdown":"https://secwatch.observer/filing/0001193125-25-273250.md","text":"https://secwatch.observer/filing/0001193125-25-273250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/0001193125-25-273250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000119312525273250/apge-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:41:33.680456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}